Business Model Breakdown
How Protara Therapeutics Inc Makes Money
TARA
Market Cap
$277M
Employees
28
The Short Version
Protara Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare and specialty diseases. Its primary product candidate, TARA-002, is currently in clinical trials for two main indications: refractory lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). The company does not currently generate revenue from product sales, relying instead on raising capital through equity offerings to fund its research and development activities and operational expenses. Its business model relies entirely on the successful clinical development, regulatory approval, and eventual commercialization of TARA-002 or other pipeline candidates.
Where the Revenue Comes From
N/A (Currently no product revenue)
Potential future licensing agreements or milestone payments (unspecified)
Who buys: Future customers would be patients with refractory lymphatic malformations and non-muscle invasive bladder cancer, as well as healthcare providers.
Why It Works (Competitive Advantages)
- ✔FDA Orphan Drug Designation for TARA-002 in specific lymphatic malformations, granting potential market exclusivity.
- ✔FDA Breakthrough Therapy and Fast Track Designations for TARA-002, accelerating development and review processes.
- ✔Proprietary IP surrounding TARA-002 as a therapeutic agent.
Economic Moat: Narrow (Intangible Assets/IP (patent protection for TARA-002), Regulatory Advantages (Orphan Drug Designation, Breakthrough Therapy Designation, Fast Track Designation))
What Our Analysis Says
DVR Score as of May 25, 2026
Protara Therapeutics (TARA) continues to represent a high-risk, high-reward investment opportunity, largely tied to the binary outcome of TARA-002. While the recent FDA Orphan Drug Designation for TARA-002 in specific lymphatic malformations reinforces its potential for market leadership and addresses a significant unmet medical need, recent financial updates temper enthusiasm. Q1 2026 saw a widened net loss of $(17.8M) and the filing of a $300M shelf registration, explicitly indicating a high probability of significant future dilution. The BLA submission timeline for TARA-002 has also been extended to 2H 2027, prolonging the period of substantial cash burn before potential approval. These financial and timeline challenges slightly outweigh the positive regulatory clarity, increasing the perceived financial risk and the hurdle to realizing its significant long-term growth potential. **Score Change Explanation:** The previous score was 4.8/10 (48/100) on 2026-03-12. The current score of 4.5/10 (45/100) reflects a -3 point adjustment due to several material changes since the last analysis. While FDA granted Orphan Drug Designation for TARA-002 in specific lymphatic malformations in April 2026, strengthening its competitive position, the company reported a widened net loss of $(17.8M) in Q1 2026 compared to $(11.9M) in Q1 2025. This increased cash burn, coupled with the May 2026 filing of a $300M shelf registration, explicitly signals a high likelihood of significant future dilution, directly impacting shareholder value. Additionally, the BLA submission timeline for TARA-002 has been clarified to 2H 2027, pushing the key binary event slightly further out and extending the period of significant cash burn. These negative financial developments and extended timeline slightly outweigh the positive regulatory clarity, leading to a minor downward adjustment in the overall score, emphasizing the elevated financial risk profile.